US 12,259,390 B2
Cancer antigen targets and uses thereof
Michel Sadelain, New York, NY (US); and Fabiana Perna, New York, NY (US)
Assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed on Feb. 19, 2020, as Appl. No. 16/795,346.
Application 16/795,346 is a division of application No. 15/966,992, filed on Apr. 30, 2018, granted, now 11,193,938.
Application 15/966,992 is a continuation of application No. PCT/US2017/045632, filed on Aug. 4, 2017.
Claims priority of provisional application 62/371,199, filed on Aug. 4, 2016.
Prior Publication US 2020/0182880 A1, Jun. 11, 2020
Int. Cl. A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/72 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); G16B 5/00 (2019.01); G16B 20/00 (2019.01); G16B 20/20 (2019.01); G16B 20/30 (2019.01); G16B 20/50 (2019.01); G16B 30/00 (2019.01); A61K 48/00 (2006.01)
CPC G01N 33/57492 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464429 (2023.05); A61K 39/464431 (2023.05); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/4748 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70575 (2013.01); C07K 14/7158 (2013.01); C07K 14/723 (2013.01); C07K 16/00 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); G01N 33/566 (2013.01); G01N 33/56972 (2013.01); G01N 33/6845 (2013.01); G16B 5/00 (2019.02); G16B 20/00 (2019.02); G16B 20/20 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); G16B 30/00 (2019.02); A61K 2039/804 (2018.08); A61K 48/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/70 (2013.01); G06F 2218/00 (2023.01)] 13 Claims
 
1. A method for identifying a target tumor surface antigen comprising:
i) identifying a plurality of cell-surface expressed proteins in a tumor sample from a proteomics database, a transcriptomics database, surface proteomics analysis of the tumor sample, and flow cytometric analysis of the tumor sample, wherein each protein of said plurality has a redundant expression in at least 2 databases; and
ii) identifying the target tumor surface antigen from said plurality of cell-surface expressed proteins wherein said target tumor surface antigen has:
a) an expression level in the tumor sample higher than its expression level in a normal sample of the type of tissue from which the tumor is derived; and
b) an expression level in a normal tissue sample that is no more than one standard deviation above the normal peak of the protein expression level distribution of a plurality of samples of normal tissues, other than the tissue from which the tumor sample is derived.